Category: News

Post

VenatoRx Awarded NIH RO1 Grant

VenatoRx has been awarded an NIH R01 Grant for novel approaches to address biodefense-related infections. The company may receive up to $6M of funding under the grant. READ FULL TEXT

Post

Venatorx Pharmaceuticals Awarded NIH RO1 Grant

Venatorx Pharmaceuticals has been awarded an NIH R01 Grant for novel approaches to address biodefense-related infections. The company may receive up to $6M of funding under the grant. READ FULL TEXT

Post

VenatoRx Completes Series A Financing

VenatoRx has completed a Series A financing round of approximately $3.5M from private investors to complement its other sources of funding and help advance its novel discovery and development programs. READ FULL TEXT

November 22, 2013November 22, 2013by In News
Post

Venatorx Pharmaceuticals Completes Series A Financing

Venatorx Pharmaceuticals has completed a Series A financing round of approximately $3.5M from private investors to complement its other sources of funding and help advance its novel discovery and development programs. READ FULL TEXT

November 22, 2013November 22, 2013by In News
Post

Venatorx Pharmaceuticals awarded funding from the Wellcome Trust

Venatorx Pharmaceuticals announced that it has received an investment of $8.9M from the Wellcome Trust Translation Fund for the “Development of novel small molecules for the treatment of antibiotic resistant bacterial infections.” Venatorx is developing new antibacterial therapeutic products to address multi-drug resistant gram negative bacteria, including resistant E. coli, K. pneumoniae, and P. aeruginosa, important...

Post

VenatoRx awarded funding from the Wellcome Trust

VenatoRx received an investment of $8.9M from the Wellcome Trust Translation Fund for the “Development of novel small molecules for the treatment of antibiotic resistant bacterial infections. READ FULL TEXT

Post

Venatorx Pharmaceuticals Awarded NIH Contract

Responding to a Broad Agency Announcement (BAA-NIAID-DMID-NIHAI2012149) solicitation titled “Development of Therapeutic Medical Countermeasures for Biodefense and Emerging Infectious Diseases”, Venatorx Pharmaceuticals was selected to execute a research and development contract around proprietary compounds that address resistant NIAID Category A, B, and C pathogens. The contract award is for up to $21.2M. READ FULL TEXT

September 16, 2013September 16, 2013by In News
Post

VenatoRx Awarded NIH Contract

VenatoRx was elected to execute a research and development contract around proprietary compounds that address resistant NIAID Category A, B, and C pathogens. The contract award is for up to $21.2M. READ FULL TEXT

Post

Venatorx Pharmaceuticals Awarded Phase II SBIR Grant

Venatorx Pharmaceuticals was awarded a Phase 2 SBIR Grant for novel approaches to address multi-drug resistant gram-negative infections. Venatorx may receive up to $3M of funding under the grant. READ FULL TEXT

September 1, 2013September 1, 2013by In News